human TP53 shRNA silencing AAV

antigen NY-CO-13; BCC7; cellular tumor antigen p53; LFS1; mutant tumor protein 53; P53; p53 tumor suppressor; phosphoprotein p53; transformation-related protein 53; TRP53; tumor protein 53; Tumor suppressor p53; tumor supressor p53

p53 is a tumor suppressor protein that is mutated or inactivated in over 50% of human cancers. Loss of function defects in p53 are the cause of the autosomal dominant familial cancer syndrome, Li-Fraumeni syndrome (LFS) that is characterized by the development of a diverse set of malignancies at very early ages. At the cellular level p53 is involved in the negative regulation of cell the cycle via its transactivational control of genes required for cell cycle progression. Depending on the physiological circumstance, p53 can promote growth arrest or apoptosis.

TP53 encodes tumor protein p53, which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity.

7157

tumor protein p53

tumor protein p53

TP53

HGNC:11998

9606.0

1182

Cellular tumor antigen p53

NM_000546

NM_001276761, NM_001276760, NM_001276699, NM_001276698, NM_001276697, NM_001276696, NM_001276695, NM_001126118, NM_001126117, NM_001126116, NM_001126115, NM_001126114, NM_001126113, NM_001126112, NM_000546, BC003596,

Aging,Alzheimer's Disease,Amyotrophic Lateral Sclerosis (ALS),Apoptosis,Autophagy,Bladder Cancer,Breast Cancer,Cancer,Cardiology,Cardiovascular,Cell Cycle,Chromatin Remodeling,Colorectal Cancer,DNA Damage/Repair,DNA Replication,EGFR Signaling,Gene Expression,Glioma,Helicase Activity,Histone Modification,Host-Virus Interactions,Huntington's Disease,Hypoxia,IFN Signaling,Immunology,Leukemia,LKB1 Signaling,Lung Cancer,MAPK Signaling,MicroRNAs in Cancer,Mitochondrion,Neurobiology,Neurodegeneration,Neurodevelopment,p53 Signaling,Parkinson's Disease,PI3K/Akt Signaling,Prostate Cancer,Replication,RNA Binding,Signal Transduction,TGF-beta Signaling,Transcription Factor/Regulator,Transcriptional Misregulation in Cancer,Tumor Suppressors/Oncoproteins,Viral Carcinogenesis,Wnt Signaling

cancer,cardiovascular,cell_biology,cell_cycle,developmental_biology,genetics,immunology,infectious_disease,neurobiology,signal_transduction,transcription_translation

human

p53 is a tumor suppressor protein that is mutated or inactivated in over 50% of human cancers. Loss of function defects in p53 are the cause of the autosomal dominant familial cancer syndrome, Li-Fraumeni syndrome (LFS) that is characterized by the development of a diverse set of malignancies at very early ages. At the cellular level p53 is involved in the negative regulation of cell the cycle via its transactivational control of genes required for cell cycle progression. Depending on the physiological circumstance, p53 can promote growth arrest or apoptosis.

Hs.654481

P04637